Discovery and druggability evaluation of pyrrolamide-type GyrB/ParE inhibitor against drug-resistant bacterial infection

• Main Authors: Xintong Zhao (Author), Jing Feng (Author), Jie Zhang (Author), Zunsheng Han (Author), Yuhua Hu (Author), Hui-Hui Shao (Author), Tianlei Li (Author), Jie Xia (Author), Kangfan Lei (Author), Weiping Wang (Author), Fangfang Lai (Author), Yuan Lin (Author), Bo Liu (Author), Kun Zhang (Author), Chi Zhang (Author), Qingyun Yang (Author), Xinyu Luo (Author), Hanyilan Zhang (Author), Chuang Li (Author), Wenxuan Zhang (Author), Song Wu (Author)
• Formato: Livro
• Publicado em: Elsevier, 2023-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

The bacterial ATP-competitive GyrB/ParE subunits of type II topoisomerase are important anti-bacterial targets to treat super drug-resistant bacterial infections. Herein we discovered novel pyrrolamide-type GyrB/ParE inhibitors based on the structural modifications of the candidate AZD5099 that was...